High-Dose UVA-1 Therapy Improves Patient-Reported Outcomes and Clinical Scores in Patients with Sclerosing Skin Disease

A clinical trial involving 21 patients with morphea or systemic sclerosis with cutaneous involvement evaluated the effects of high-dose UVA-1 therapy on sclerosing skin disease. Patients underwent 30 treatments, and both patient-reported outcomes (PROs) and clinical scores were assessed. The study found significant improvements in PROs, including Skindex-16 and PROMIS-PF scores, as well as clinical measures like the modified Rodnan Skin Score, LoSCAT, PGA, and HAMIS scores. These results suggest that high-dose UVA-1 therapy is effective in improving both subjective and objective outcomes in sclerosing skin disease, though further randomized trials are recommended to confirm these findings.